Assayed reagent kit Anti human insulin antibody(INS-Ab) for Automatic immunoassay analyzer in DIABETES

Assayed reagent kit Anti human insulin antibody(INS-Ab) for Automatic immunoassay analyzer in DIABETES

Project Introduction

Insulin antibody (INS-Ab): Insulin antibodies appear in two cases: one is the drug antibody (IA) produced by insulin therapy in patients receiving exogenous insulin treatment, which is mainly related to the purity of insulin preparations; one These are called insulin autoantibodies (IAAs) in patients who have never been treated with insulin. The two antibodies are currently methodologically indistinguishable, but are usually IA, almost all of the IgG type. It is mainly used for the evaluation of high affinity and low reactivity of preparations used in insulin therapy, and is also used to sign allergic reactions to insulin; IAA is used for the diagnosis of type 1 diabetes and one of the methods for distinguishing between type 1 diabetes and type 2 diabetes; occult type The discovery of type 1 diabetes, the evaluation of autoimmune syndrome of autoimmune hypoglycemia and insulin, and the examination of autoantibodies as an autoimmune disease.

Clinical Significance

Abnormal result: serum anti-insulin antibody is positive

(1) To guide the treatment of insulin-dependent diabetes patients: high titer of insulin antibodies in the circulation is the main cause of severe insulin resistance. Detection of A-IAb can guide the dosage of insulin and provide a basis for the treatment of drug-resistant diabetes when the antibody titer is high. -acting insulin can be increased moderately. When antibody titers are low, use long-acting insulin.

(2) Judging the prognosis of insulin-dependent diabetes mellitus: a low insulin release curve and a high titer of insulin antibodies indicate that the patient is not pancreatic islet failure, indicating a stable condition. On the contrary, it indicates that the prognosis of insulin failure is poor.

(3) Anti-insulin antibodies can also be detected in individual patients with hyperthyroidism. People who need to be checked: dependent diabetes patients, patients with hyperthyroidism

Zecen Biotech CO., LTD., founded in 2011, is a leading Chinese diagnostics manufacturer specializing in in-vitro diagnostics devices and reagents. Zecen focus on the Chemiluminescent immunoassay (CLIA) field. With all products CE marked, our market presence currently spreads from across China to other countries including India, Switzerland, Russia etc., Zecen is expanding its footprint to become a global brand.

Zecen is the only enterprise with independent intellectual property rights in the entire chemiluminescence industry chain in China, including reagent, instrument, magnetic microbead, and reagent raw material. Our current products include more than 100 assays, from thyroid, inflammation, diabetes, tumer markers, immune disorders, hormones to cardiac markers. Our ever-expanding test menu helps our customers and collaborators keep up with the demands of healthcare sector. Zecen is striving for innovation and perfection to deliver the best products to the customers.

As a manufacturer, Zecen provide the OEM, ODM and other customized service of all products. We have the core R&D centers and innovative ability to lay a solid foundation for developing the broadest range of CLIA analyzers and test menu. High-quality sales and after-sales links provide the more intimate service. The patent and CE certification give us the confident sending all over the world, and more than 50 companys in the requiement of customized and have a long term coorperation with Zecen.